Envoy Medical (NASDAQ:COCH) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?

Key Points

• Envoy Medical shares fell below their 200-day moving average, trading as low as $6.80 and last at $6.81, compared with the average of $6.88.
• Analyst views are mixed: the average rating is Hold with a $21 price target, while HC Wainwright maintained Buy and an $18 target. It raised its FY2026 loss estimate to $2.61 per share but forecast a larger FY2027 loss than previously expected.
• In its latest quarter, Envoy Medical reported a loss of $0.50 per share, better than the $0.67 loss analysts expected, while revenue of $0.07 million came in below the $0.09 million consensus.

Shares of Envoy Medical, Inc. (NASDAQ:COCH - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.88 and traded as low as $6.80. Envoy Medical shares last traded at $6.81, with a volume of 12,917 shares traded.

Latest Envoy Medical News

Here's some of the latest news about COCH:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.61 from a projected loss of $3.10, indicating a smaller expected loss. The firm maintained its Buy rating and $18 price target.
• Positive Sentiment: Short interest fell 84.4% in October, potentially reflecting reduced bearish positioning. Envoy Medical Shares Shorted: Short Interest Down 84.4% in October
• Negative Sentiment: HC Wainwright cut its loss estimates for each quarter of 2027 and for full-year 2027. Its FY2027 EPS forecast moved to a loss of $2.25 from $1.80, signaling expectations of deeper losses than previously forecast.

Analyst Ratings Changes

COCH has been the topic of several research analyst reports. Loop Capital set a $20.00 target price on Envoy Medical in a research note on Monday, July 27th. Lake Street Capital upped their target price on Envoy Medical from $2.50 to $25.00 and gave the company a "buy" rating in a report on Tuesday, October 27th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Envoy Medical in a research note on Monday. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Envoy Medical in a report on Monday, October 19th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Envoy Medical has an average rating of "Hold" and an average price target of $21.00.

Envoy Medical Stock Performance

The stock's 50-day moving average price is $6.81 and its two-hundred day moving average price is $6.88. The stock has a market capitalization of $52.57 million, a PE ratio of -1.48 and a beta of 2.03.

Envoy Medical (NASDAQ:COCH - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.17. Envoy Medical had a negative net margin of 9,026.41% and a negative return on equity of 5,250.23%. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.09 million. On average, analysts predict that Envoy Medical, Inc. will post -2.61 earnings per share for the current fiscal year.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor. The company's lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body's natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.